Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Journal of the American Academy of Dermatology
|
March 18, 2018
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
Alexander Egeberg, Jashin J Wu, Neil Korman, et al.
Seminars in Arthritis and Rheumatism
|
June 11, 2015
Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)
Deepan S Dalal, Yih Chang Lin, Danielle M Brennan, et al.
Journal of the American Academy of Dermatology
|
October 30, 2017
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Kevin L Winthrop, Neil Korman, William Abramovits, et al.
Journal of the American Academy of Dermatology
|
July 16, 2005
Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis
Jon M Hanifin, Amy S Paller, Lawrence Eichenfield, et al.
Journal of Drugs in Dermatology : JDD
|
April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes
Leon Kircik, Jerry Bagel, Neil Korman, et al.
Pediatric Dermatology
|
January 31, 2013
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States
Katherine Mercy, Mary Kwasny, Kelly M Cordoro, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Journal of the American Academy of Dermatology
|
March 18, 2018
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
Alexander Egeberg, Jashin J Wu, Neil Korman, et al.
Seminars in Arthritis and Rheumatism
|
June 11, 2015
Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)
Deepan S Dalal, Yih Chang Lin, Danielle M Brennan, et al.
Journal of the American Academy of Dermatology
|
October 30, 2017
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
Kevin L Winthrop, Neil Korman, William Abramovits, et al.
Journal of the American Academy of Dermatology
|
July 16, 2005
Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis
Jon M Hanifin, Amy S Paller, Lawrence Eichenfield, et al.
Journal of Drugs in Dermatology : JDD
|
April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes
Leon Kircik, Jerry Bagel, Neil Korman, et al.
Pediatric Dermatology
|
January 31, 2013
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States
Katherine Mercy, Mary Kwasny, Kelly M Cordoro, et al.
Page
of 2